UK markets close in 1 hour 3 minutes

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
46.25-0.10 (-0.22%)
As of 03:11PM BST. Market open.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Sector(s)
Industry
Full-time employees290

Key executives

NameTitlePayExercisedYear born
Mr. Mauro Severino AjaniFounder & Exec. Chairman420.79kN/A1955
Mr. Alessandro E. Della Cha LL.MCEO & Exec. Director637.65kN/A1963
Mr. Ngo Dinh NhanHead of R&D - AI & Biomedical ITN/AN/A1979
Mr. Giulio EvangelistiHead of Production, AI & Biomedical ITN/AN/A1970
Mr. Niall DonnellyChief Financial OfficerN/AN/A1972
Mr. Marco LecchiChief Operating OfficerN/AN/A1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/AN/A1973
Mr. Luigi LongoChief Scientific OfficerN/AN/A1979
Ms. Hazel WinchesterHead of Investor RelationsN/AN/A1971
Mr. Biagio ViganoChief People OfficerN/AN/A1974
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Corporate governance

Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.